Latest news with #Inc.
Business Wire
12 hours ago
- Business
- Business Wire
Benchmark Announces Appointment of Glynis A. Bryan to Board of Directors
TEMPE, Ariz.--(BUSINESS WIRE)-- Benchmark Electronics, Inc. (NYSE: BHE), a global provider of engineering, design, and manufacturing services, announces the appointment of Glynis A. Bryan to its Board of Directors. Ms. Bryan brings a wealth of financial and operational expertise to Benchmark's Board. She recently retired as Chief Financial Officer of Insight Enterprises, Inc., where she served from 2007 to 2024. Prior to Insight, Ms. Bryan held senior financial leadership positions at Swift Transportation Co., APL Logistics, and Ryder System, Inc. She currently serves on the Boards of Ameriprise Financial, Inc., Pinnacle West Capital Corporation, and WESCO International, Inc. 'We are thrilled to welcome Glynis to our Board,' said Jeff Benck, President and CEO of Benchmark. 'With over 20 years as a Chief Financial Officer, including her tenure at Insight Enterprises, Inc., Glynis has demonstrated exceptional skills in financial planning, mergers and acquisitions, and strategic growth initiatives. Her leadership has been instrumental in guiding companies through complex financial landscapes, making her a valuable asset to Benchmark's board. 'With her extensive background in corporate governance, Glynis offers a strategic perspective that aligns perfectly with Benchmark's commitment to excellence,' said David W. Scheible, Chairman of the Board. 'Her insights from serving on multiple prominent boards will enhance our decision-making processes and support our long-term objectives.' To learn more about Benchmark's Board of Directors, please visit About Benchmark Electronics, Inc. Benchmark provides comprehensive solutions across the entire product lifecycle; leading through its innovative technology and engineering design services; leveraging its optimized global supply chain; and delivering world-class manufacturing services in the following industries: commercial aerospace, defense, advanced computing, next-generation communications, medical, complex industrials, and semiconductor capital equipment. Benchmark's global operations include facilities in seven countries and its common shares trade on the New York Stock Exchange under the symbol BHE.
Business Wire
20 hours ago
- Health
- Business Wire
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia ( has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM). Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities. 'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.' The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system. 'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.' As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day. The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function. ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes. For more information about ZAP Surgical and the ZAP-X system, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Business Wire
20 hours ago
- Business
- Business Wire
Phase Genomics Launches ProxiMeta™ Starter and Elite Bundles to Expand Access to Genome-Resolved Metagenomics
SEATTLE--(BUSINESS WIRE)-- Phase Genomics, Inc., a leader in genomic technology development, today announced the launch of its new ProxiMeta Starter and Elite Bundles, comprehensive product offerings that make genome- and mobilome-resolved metagenomics more accessible for researchers across microbiome, environmental and public health applications. Built on Phase Genomics' award-winning Hi-C metagenomics platform, the streamlined, full-service solutions accelerate discovery from within complex microbial communities. 'We built the ProxiMeta bundles to meet researchers exactly where they are, whether just getting started or leading large-scale research projects. Research doesn't look the same today as it did even last year. Labs are being asked to do more with fewer resources across the board, and we're here to help,' said Ivan Liachko, PhD, CEO and co-founder of Phase Genomics. 'The ProxiMeta bundles offer a flexible platform that evolves with a researcher's career and their science.' The two new bundles provide a scalable entry point for new users and a hands-off option for labs looking to outsource highly specialized technical workflows. The Starter and Elite bundles for Hi-C metagenomics combine robust sequencing, dynamic bioinformatics and personalized scientific support into ready-to-use formats, without the constraints of 16S-based techniques or culturing. The ProxiMeta Starter Bundle is tailored for early-career researchers new to next-generation metagenomics, offering an affordable on-ramp to advanced microbial insights for up to two samples with guaranteed success on library prep. If the initial library preparation fails, Phase Genomics will re-prep the sample at no additional cost. Starter includes hands-on support from Phase Genomics scientists. Learn more here. The ProxiMeta Elite Bundle offers a turnkey, remote extension of lab operations for experienced investigators with active funding and limited bench time. The bundle includes deep metagenomic shotgun sequencing and Hi-C assembly for up to eight samples, performed entirely in-house at Phase Genomics. Learn more here. ProxiMeta Classic is still available as an à la carte option for researchers who prefer to customize their project scope or perform sequencing and analysis in-house. Classic delivers the same high-resolution capabilities with the flexibility of tailored support when needed. The ProxiMeta platform has been heavily cited in leading peer-reviewed journals for its ability to generate high-quality genomes, resolve microbial population structure and link mobile genetic elements like plasmids and phages to their microbial hosts. The ProxiMeta Starter and Elite Bundles are available beginning today, June 19, 2025. For more information or to request a consultation, stop by booth 1109 at ASM 2025 or visit: Follow Phase Genomics on X and LinkedIn for the latest information. About Phase Genomics Phase Genomics applies proprietary ultra-long-range genome sequencing technology to enable genome assembly, microbiome discovery, as well as analysis of genomic integrity and chromosomal aberrations. In addition to a comprehensive portfolio of laboratory and computational services and products, including reagent kits and genomic services, they also offer an industry-leading genome and metagenome assembly and analysis software. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company's mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.
Business Wire
21 hours ago
- Health
- Business Wire
Newly Published Health Economics Study Demonstrates In-Office Ear Tube Procedures with Hummingbird TTS Significantly Reduce Healthcare Costs
GOLDEN VALLEY, Minn.--(BUSINESS WIRE)-- Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the publication of a health economic study assessing the financial impact of shifting pediatric tympanostomy tube (ear tube) placement from operating room to in-office settings. The analysis, published in the Journal of Medical Economics, demonstrates significant cost savings potential for Commercial and Medicaid health insurance payers that provide access to in-office ear tube procedures utilizing the Hummingbird ® Tympanostomy Tube System (TTS). "This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office." Dr. Gene Liu, Study Co-Author Key findings from the study include 1: Current costs of ear tube surgeries are estimated to be $3.5 billion annually for the US Healthcare System: Ear tube surgeries in a Hospital Outpatient Department (HOPD) on average cost over $5,700 for a commercial plan and $2,100 for a Medicaid plan Higher costs of OR-based surgeries are driven by the costs of the operating room, anesthesia, pre- and post-surgery care, and additional pre-operative testing Shifting ear tube procedures from the OR to the Office could save: Up to $3,743 per patient (65% cost savings) for a Commercial health plan Up to $519 per patient (24% cost savings) for a Medicaid health plan The procedural cost savings were significant even after accounting for the increased costs of pediatric in-office ear tube procedures, including the costs of the Hummingbird ® TTS Pediatric ear tube surgeries historically have been performed in the operating room (OR) under general anesthesia. However, the procedure can be safely and effectively performed in an office setting by using the Hummingbird ® TTS, helping pediatric patients avoid risks associated with operating room surgeries and general anesthesia exposure 2. This analysis demonstrates that in addition to the important clinical and safety benefits, Payers may also experience significant cost savings. 'Shifting ear tube placement into the office with the Hummingbird ® Device has improved patient access and offered families an important alternative to OR-based surgeries,' said Dr. Gene Liu, Pediatric Otolaryngologist at Cedars-Sinai Medical Center. 'This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office. My hope is that these findings encourage payers to establish sustainable reimbursement rates that expand access to this safe and cost-effective option.' To support patient access to pediatric in-office ear tube procedures with tympanostomy tube delivery devices, the Centers for Medicare & Medicaid Services (CMS) established add-on HCPCS Code (+G0561) in the 2025 Physician Fee Schedule 3. CMS stated in the 2025 PFS, 'These minimally invasive, in-office procedures can offer significant benefits, including reduced risks associated with general anesthesia, quicker recovery, fewer infections, and improved access to care.' The new add-on G code facilitates fair reimbursement to providers for the incremental work and practice expenses (including device costs) involved in performing pediatric ear tube procedures in-office. This is the first economic study to evaluate the economic impact of utilizing the add-on code +G0561. 'This study reinforces what we have seen in our Health System, where we have been offering in-office ear tube procedures with the Hummingbird Device since 2021,' shared Dr. Mark Gerber, Pediatric Otolaryngologist at Phoenix Children's Hospital. 'Providing a mechanism for reimbursement for the incremental costs of the pediatric procedure will remove a significant barrier to utilization and save healthcare dollars.' About Preceptis Medical Founded in 2011, Preceptis Medical is an innovative medical technology company dedicated to providing less invasive ear tube procedure options for pediatric patients. The FDA-cleared Hummingbird ® Tympanostomy Tube System (TTS) streamlines ear tube placement, which enables the procedure to be performed with only a topical anesthetic. The Hummingbird, indicated for use in patients 6 months of age and older, provides a simple and efficient option for ENTs and parents while reducing healthcare costs. For more information, please visit Moynihan, M., Ross, R., Delgado, J., Gerber, M., & Liu, G. (2025). Economic impact of in-office pediatric tympanostomy tube placement using a tympanostomy tube delivery device in a commercially- and Medicaid-insured US population. Journal of Medical Economics, 28 (1), 899–909 Truitt MD, Theodore O., et al. 'In-office insertion tympanostomy tubes in children using single-pass device' Laryngoscope Investigative Otolaryngology. 2021;6:325-331.
Yahoo
a day ago
- Business
- Yahoo
Interactive Brokers Group, Inc. (IBKR) Dips More Than Broader Market: What You Should Know
In the latest trading session, Interactive Brokers Group, Inc. (IBKR) closed at $52.60, marking a -74.73% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.03%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.13%. Heading into today, shares of the company had lost 1.03% over the past month, outpacing the Finance sector's loss of 1.73% and lagging the S&P 500's gain of 0.6%. The upcoming earnings release of Interactive Brokers Group, Inc. will be of great interest to investors. The company is expected to report EPS of $1.73, down 1.7% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.32 billion, up 7.65% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $7.06 per share and revenue of $5.36 billion, indicating changes of +0.43% and +2.62%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Interactive Brokers Group, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Interactive Brokers Group, Inc. is currently a Zacks Rank #4 (Sell). Valuation is also important, so investors should note that Interactive Brokers Group, Inc. has a Forward P/E ratio of 29.51 right now. For comparison, its industry has an average Forward P/E of 14.59, which means Interactive Brokers Group, Inc. is trading at a premium to the group. We can additionally observe that IBKR currently boasts a PEG ratio of 2.82. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. IBKR's industry had an average PEG ratio of 1.2 as of yesterday's close. The Financial - Investment Bank industry is part of the Finance sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 40% of all industries, numbering over 250. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Interactive Brokers Group, Inc. (IBKR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
